Spero Therapeutics (SPRO) Invested Capital (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Invested Capital data on file, last reported at $52.9 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 56.54% year-over-year to $52.9 million; the trailing twelve-month figure through Mar 2026 stood at $52.9 million (up 56.54% YoY), and the FY2025 full-year result was $59.0 million, up 27.96% from the prior year.
• Invested Capital for Q1 2026 stood at $52.9 million, down from $59.0 million in the prior quarter.
• Across five years, Invested Capital topped out at $106.9 million in Q4 2023 and bottomed at $26.5 million in Q3 2025.
• The 5-year median for Invested Capital is $54.8 million (2023), against an average of $57.8 million.
• The widest annual swing landed in 2022, when Invested Capital sank 70.84%; it then soared 64.61% in 2023.
• A 5-year view of Invested Capital shows it stood at $75.9 million in 2022, then jumped by 40.77% to $106.9 million in 2023, then slumped by 56.85% to $46.1 million in 2024, then gained by 27.96% to $59.0 million in 2025, then declined by 10.31% to $52.9 million in 2026.
• The last three Invested Capital figures came in at $52.9 million (Q1 2026), $59.0 million (Q4 2025), and $26.5 million (Q3 2025), per Business Quant data.

Peer Comparison